Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | RAD51 | Q06609 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | YAP1 | P46937 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26064226 | 1.00 | MEN1 (0.58) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL25432110 | 1.00 | MEN1 (0.58) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL26064198 | 0.93 | RAD51 (0.58) | MEN1KMT2ARAD51 | |
| SCHEMBL25434505 | 0.93 | MEN1 (0.49) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL26064199 | 0.93 | RAD51 (0.58) | MEN1KMT2ARAD51 | |
| SCHEMBL25432658 | 0.93 | RAD51 (0.55) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL25432966 | 0.93 | RAD51 (0.58) | MEN1KMT2ARAD51 | |
| SCHEMBL25431800 | 0.93 | MEN1 (0.49) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL25431905 | 0.93 | RAD51 (0.53) | MEN1KMT2ARAD51KDM4EGRIN2D | |
| SCHEMBL25433024 | 0.92 | MEN1 (0.50) | MEN1KMT2ARAD51KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | claimed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | RAD51, ERCC4, ERCC2 | MEN1 1316/4885KMT2A 2879/4885RAD51 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.